BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 23, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Debiopharm presents new Fabl inhibitor for resistant
Neisseria
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Infection
Debiopharm presents new Fabl inhibitor for resistant
Neisseria
May 2, 2024
No Comments
Debiopharm International SA has developed and presented a Fabl inhibitor, gofabicin, for the treatment of antibiotic-resistant
Neisseria gonorrhoeae
.
BioWorld Science
Conferences
New compound
European Congress of Clinical Microbiology and Infectious Diseases
Infection
